Gilead Sciences, Inc. Price Today
Gilead Sciences, Inc.
GILD
Healthcare
$95.47B
💰
Market Cap
17.6
💸
Price to Earnings
$4.3
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
13 |
Strong Buy |
6 |
Hold |
16 |
Sell |
1 |
Strong Sell |
0 |
GILD Price Forecast Target
76.6 👉 109.4 +43%
GILD EPS Forecast
4.3 👉 6.8 +57%
Financials
Profit Margin
20 %
Revenue Growth
5.4 %
Dividend
$ 3.0
Held Percent
0.1% - Insiders
86.8% - Institutions
13.1% - Public
Major Fund Holders
-
💰 Blackrock Inc. $9.7B
-
💰 Vanguard Group Inc $8.7B
-
💰 Capital World Investors $6.2B
-
💰 State Street Corporation $4.6B
-
💰 Capital Research Global Investors $4.5B
Stock Ideas
Stanley Druckenmiller Portfolio
Stanley Druckenmiller is a legendary hedge fund manager who has made billions of dollars for his investors. His current portfolio is heavily invested in gold, silver, and other precious metals. He also owns shares in several technology and healthcar…
David Tepper Portfolio
David Tepper is a renowned billionaire investor, widely known for his incredible success during the 2009 financial crisis where he made a staggering $4 billion. His financial prowess has earned him the distinction of being the 258th richest individ…
Scott Ferguson Portfolio
With a strong background as a protégé of Bill Ackman, founder of Pershing Square Capital Management, Scott Ferguson has honed his skills and expertise in the art of activist investing. He possesses the ability to identify undervalued companies with …
Jim Simons Portfolio
Jim Simons, the mastermind behind the Medallion Fund, has achieved such extraordinary returns that he has skyrocketed to the ranks of the world's wealthiest individuals. The secret to his success lies in the fund's implementation of high-frequency t…📮FAQ
Some Frequently Asked Questions.
The Gilead Sciences, Inc. industry is Drug Manufacturers—General
The Gilead Sciences, Inc. sector is Healthcare
The Gilead Sciences, Inc. forecasted predicted Price to Earnings PE ratio is 11.2
The Gilead Sciences, Inc. Price to Earnings PE ratio is 17.6
The Market Capitalization of Gilead Sciences, Inc. is $95.47B
There are total of 1244456835 float shares with 86.8% held by Institutions and 0.1% held by insiders
The MGilead Sciences, Inc. forecasted Earnings per Share EPS is $6.8
The Gilead Sciences, Inc. Earnings per Share EPS is 4.3
The Gilead Sciences, Inc. company has $21624000000 gross profits with 20 profit margins
The Gilead Sciences, Inc. Earnings Growth is -0.088% with -0.087% quarterly earnings growth
The Gilead Sciences, Inc. Revenue is $27381999616 with 0.054 revenue growth
The price target for Gilead Sciences, Inc. stock is $109.4 for the high target and $67.0 for the low target
The consensus analyst recommendations for Gilead Sciences, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Gilead Sciences, Inc. is Buy, with the following breakdown:
- Buy: 13
- Strong Buy: 6
- Hold: 16
- Sell: 1
- Strong Sell: 0
The Beta of Gilead Sciences, Inc. is 0.3
The dividend of Gilead Sciences, Inc. is $3.0
The dividend yield of Gilead Sciences, Inc. is 0.0392%
The biggest institutional and mutual fund holders of Gilead Sciences, Inc. stock are
- Blackrock Inc.
- Vanguard Group Inc
- Capital World Investors
- State Street Corporation
The Gilead Sciences, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0